Breaking Finance News

RUMOR ROUNDUP- Why Novavax is up 14 Percent

5119051558_97dd14cf4b_zShares of Novavax (NASDAQ: NVAX) are up 14 percent in premarket trading but media outlets aren’t reporting any notable news. However, traders posting to social media sites have some ideas.

Novamax is a $379 million company that closed at $2.51 Wednesday. Over the past six months the stock has added nearly 33 percent and year to date, 27 percent. It’s last earnings report disappointed investors when it announced a 51 percent decline in overall revenue and an EPS loss of ($0.08) which was larger than its loss of ($0.05) in the same quarter, 2012.

The stock is active, trading 1.6 million shares daily and has 5 “Buy” ratings and 2 “Strong Buy” ratings.

From Twitter:



Real Time Twitter Feed:

Company Profile:

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company’s technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company’s VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.


[stock-tools exchange="NASDAQ" symbol="NVAX" image_height="230" image_width="350"]

Disclosure: At the time of this writing, the author had no position in the company mentioned.

New to Breaking Finance News? Read about our format here.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.